title: Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
abstract: BACKGROUND
  Surgery can cure a significant percentage of ovarian carcinoma confined to the pelvis. Nevertheless, there is still a 10-50% recurrence rate. We administered paclitaxel/carboplatin as adjuvant treatment in early-stage ovarian carcinoma.
  
  
  METHODS
  Patients with stages Ia or Ib, Grade 2 or 3 and Ic to IIb (any grade) were included. Patients were treated with 4 cycles of Paclitaxel 175 mg/m2 and Carboplatin [area under the curve (AUC) 6 (Calvert Formula)] every 3 weeks.
  
  
  RESULTS
  Sixty-nine patients with no residual disease following cytoreductive surgery and minimal or modified surgical staging were included in this analysis. Grade 3 or 4 neutropenia occurred in 29.9% of patients, while neutropenic fever was reported in 4.5%. Neurotoxicity (all Grade 1 or 2) was reported in 50% of cases. Median follow-up was 62 months. 5-year overall survival (OS) and relapse-free survival (RFS) were: 87% (95% confidence intervals [CI]: 78-96) and 79% (95% CI: 69-89), respectively. Significantly fewer patients with stages Ic-IIb and tumor grade 2 or 3 achieved a 5-year RFS than patients with only one of these two factors (73% vs 92%, p = 0.03).
  
  
  CONCLUSIONS
  Paclitaxel/Carboplatin chemotherapy is a safe and effective adjuvant treatment in early-stage ovarian carcinoma. Patients with stages Ic-IIb and tumor grade 2 or 3 may benefit from more extensive treatment.
authors.affiliation: Department of Clinical Therapeutics, Medical School, University of Athens, Athens, Greece. abamias@med.uoa.gr
authors.forename: Aristotle
authors.initials: A
authors.lastname: Bamias
authors.forename: Christos
authors.initials: C
authors.lastname: Papadimitriou
authors.forename: Eleni
authors.initials: E
authors.lastname: Efstathiou
authors.forename: Alexandros
authors.initials: A
authors.lastname: Rodolakis
authors.forename: Georgios
authors.initials: G
authors.lastname: Vlahos
authors.forename: Zannis
authors.initials: Z
authors.lastname: Voulgaris
authors.forename: Georgios
authors.initials: G
authors.lastname: Bozas
authors.forename: Georgios
authors.initials: G
authors.lastname: Fountzilas
authors.forename: Gerassimos
authors.initials: G
authors.lastname: Aravantinos
authors.forename: Evagelia
authors.initials: E
authors.lastname: Razis
authors.forename: Dimitra
authors.initials: D
authors.lastname: Gika
authors.forename: Meletios A
authors.initials: MA
authors.lastname: Dimopoulos
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006115:Greece; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D016190:Carboplatin; D017239:Paclitaxel